Key Advances in Gynecologic Cancers: Expert Insight for Incorporating New Clinical Evidence
  • CME
  • CE

Review this expert analysis by Ritu Salani, MD, MBA, and Eva Y. Pan, PharmD, BCOP, focusing on the most recent practice-changing evidence for patients with ovarian, endometrial, and cervical cancers.
Eva Y. Pan, PharmD, BCOP
Ritu Salani, MD, MBA
Physicians: maximum of 1.25 AMA PRA Category 1 Credits
Registered Nurses: 1.25 Nursing contact hours
Pharmacists: 1.25 contact hours (0.125 CEUs)
Released: May 13, 2022 Expiration: May 12, 2023

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess for appropriate predictive biomarkers in gynecologic cancers to guide treatment selection and clinical trial eligibility
  • Evaluate current and emerging practice-changing clinical data on checkpoint inhibitors and PARP inhibition as single-agent or combination therapies in cervical, endometrial, and ovarian cancer
  • Plan treatment strategies for patients with cervical, endometrial, and ovarian cancers that incorporate novel therapies and combination regimens
  • Select maintenance therapy for patients with ovarian cancer with or without BRCA mutations or other homologous recombination repair deficiencies in the frontline and relapsed settings
  • Describe the role of immune checkpoint inhibitor-based therapy in endometrial cancer classified as microsatellite stable

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Ritu Salani, MD, MBA

Professor and Division Director
OB/GYN and Gynecologic Oncology
University of California, Los Angeles
Los Angeles, California

Ritu Salani, MD, MBA, has disclosed that she has received consulting fees from Arcus Biosciences, Genentech, GlaxoSmithKline, Instil Bio, Merck, and Seagen, and research support from Regeneron Pharmaceuticals.
Eva Y. Pan, PharmD, BCOP

Clinical Oncology Pharmacy Specialist
Yale-New Haven Hospital
New Haven, Connecticut

Eva Y. Pan, PharmD, BCOP, has no relevant conflicts of interest to report.

Staff

Jerfiz Constanzo, PhD, MBA
Scientific Director
Jerfiz Constanzo, PhD, MBA, has no relevant conflicts of interest to report.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Vice President, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Krista Marcello

Senior Director, Educational Strategy
Hematology and Oncology

Krista Marcello has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, MSN, NP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kay Orbaugh, MSN, NP, AOCNP, has received speaker fees from AstraZeneca, Bristol Myers Squibb, DSI, Gilead Sciences, Lilly, Morphosys, Pfizer, Regeneron, and Sanofi.
Jim Mortimer

Senior Director, Oncology Programs and Partnership Development

Jim Mortimer had individual publicly traded stocks/stock options in AstraZeneca.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for medical oncologists, gynecologic oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with gynecologic cancers.

Goal

The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with gynecologic malignancies.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-138-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 13, 2022, through May 12, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: November 14, 2022 Expired: November 13, 2023

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP Jubilee Brown, MD person default Elisabeth Diver, MD person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD David Scott Miller, MD, FACOG, FACS person default Mansoor Raza Mirza, MD Prof Isabelle Ray-Coquard, MD, PhD Angeles Alvarez Secord, MD, MHSc Ignace Vergote, MD, PhD Released: November 10, 2022

Expert commentary on new clinical trial data in cervical cancer and ovarian cancer, from Clinical Care Options (CCO)

Susana Banerjee, MBBS, MA, PhD, FRCP person default Mansoor Raza Mirza, MD Released: November 3, 2022

Expert commentary on PARP inhibitors in ovarian cancer, from Clinical Care Options (CCO)

person default Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Released: October 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings